Suspected iron dextran-related adverse drug events in hemodialysis patients
- 1 April 2001
- journal article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 37 (4), 743-749
- https://doi.org/10.1016/s0272-6386(01)80123-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Iron Metabolism in End‐Stage Renal DiseaseSeminars in Dialysis, 1999
- Toxicity of parenteral iron dextran therapyKidney International, 1999
- Strategies for iron supplementation: Oral versus intravenousKidney International, 1999
- Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium.Nephrology Dialysis Transplantation, 1998
- Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patientsNephrology Dialysis Transplantation, 1996
- Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patientsNephrology Dialysis Transplantation, 1996
- Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementationAmerican Journal of Kidney Diseases, 1995
- Anaphylactoid Reactions in Dialysis Patients: Pathogenesis and ManagementSeminars in Dialysis, 1995
- Efficacy of oral iron therapy in patients receiving recombinant human erythropoietinAmerican Journal of Kidney Diseases, 1995
- Iron Absorption in Chronic Renal DiseaseClinical Science, 1970